US $ 2 AstraZeneca Corona 19 Vaccine, US $ 4 … “Price varies according to quantity”

Entry 2020.12.19 07:05

Even if countries around the world purchase Corona 19 vaccine from the same company, the purchase price was found to be different. AstraZeneca’s Corona 19 vaccine, which the Korean government will supply nationwide in February next year, is at the $ 2 level in the European Union, but $ 4 in the United States. It is an analysis that influenced the situation in each country and the amount of purchases.

According to the Washington Post (WP) on the 18th (local time), the price for a single dose of AstraZeneca Corona 19 vaccine was $ 2.19 in the EU, 45.3% cheaper than in the United States ( 4 dollars).

The Corona 19 vaccine from Pfizer and German Bioentech was also $ 14.76 in the EU, 24.3% cheaper than in the US ($ 19.5), and the Sanofi-GlaxoMiscline (GSK) vaccine too It cost $ 9.3 in Europe, 11.4 in the US ($ 10.5). % Was less.

On the other hand, the cost of a single dose of Corona 19 vaccine developed by Modena in the United States is $ 18 in the EU, which is 20% more expensive than in the United States ($ 15). The Janssen (Johnson & Johnson) vaccine in the US was also $ 10.46 in the EU, 4.6% higher than in the US ($ 10).

WP analyzed the prices of Pfizer’s COVID-19 vaccine in the US and Europe, “some may have reflected that the EU subsidized the development of this vaccine.” The EU and Germany donated $ 580 million to Bioentech, which jointly developed the Pfizer vaccine.

WP also saw that there may be a price difference depending on the special contracts of the contract, such as provisions limiting the liability of pharmaceutical companies when side effects occur.

The Korean government has signed a contract to purchase a COVID-19 vaccine with AstraZeneca, and only purchase terms and supply confirmations have been signed with Pfizer, Modena, and Janssen. The government plans to close the vaccine supply contract with Pfizer and Moderna in December and with Janssen in January next year.

Im In-taek, Head of the Health Industry Policy Office of the Ministry of Health and Welfare, said at the Corona 19 briefing on the 18th: “The pricing policy of global vaccine companies is a policy of discrimination and discriminates according to whether they are in high-income countries or poor countries. ” According to discrimination.